At Solpharma we help pharmaceutical companies develop their business in global markets. Based on our extensive network of business contacts, we craft beneficial partnerships for manufacturers, rights holders, distributors and developers of new products and technologies.
Each go-to-market process is different and calls for an individual approach. That is why we stay closely involved with every client, accompanying them all the way from negotiations to signed agreements. And we continue to assist long after the first purchase order is issued to ensure smooth supply, repeat orders and long-term business.
Solpharma provides business development services to pharmaceutical companies. Since our founding in 2003, we have helped dozens of medium and small manufacturers gain inroads into mass and niche markets around the globe. Connected with medical experts and stakeholders across the supply chain, we also scout new products for local distributors and find strategic partners for early stage ventures.
At Solpharma we believe that successful business development is more than matchmaking between the right players. For each product and market we develop a specific go-to-market strategy, choosing the appropriate mode of operation, whether that involves distribution and licensing agreements or sale of marketing authorization and dossiers, technology transfer or co-development. Supporting our clients on the regulatory, commercial and logistic levels, we make sure that agreements translate into revenues and long-term partnerships.
Over the past decade, we have facilitated over 100 agreements for clients developing prescription drugs, medical devices, dietary supplements and cosmetics. We reach out to over 50 countries on all continents. In 2010, Solpharma took an active role in establishing Ativa Pharma, a distributor and marketing company in Mexico which then merged with the Canadian Paladin Labs and was later acquired by Grupo Somar, an Endo affiliate.
Confidentiality is a fundamental value at Solpharma. Having facilitated over 100 agreements, the success stories below offer just a brief overview over our activities.
Sales revenue: 1.6 million USD
Markets: Israel, Turkey, Venezuela and Spain
Sales revenue: over 12 million Euros
Sales revenue: over 3.4 million Euros
Sales revenue: over 3.1 million Euros
Market: New Zealand
Sales revenue: 1.7 million Euros
Sales revenue: over 1 million Euros.
Client: R&D company specializing in formulations of complex products
Market: Latin America
Solpharma successfully connected the R&D company with the Latin American affiliate of a multinational Pharma corporation.
The new partner provides both the manufacturing expertise and marketing infrastructure to successfully bring the drug to a commercial stage and distribute it in Latin America.
Market: Western Europe
Market: Europe, Latin America and South Africa
Sales revenue: over 1.5 million USD
Product: Pediatric OTC product
Sales revenue: over 1.8 million USD
Having identified a demand for specialized products in the Mexican market, Solpharma in conjunction with local partners set up Ativa Pharma, a marketing and distribution company. As its portfolio of foreign niche products penetrating the Mexican market expanded, Ativa Pharma was acquired by Endo’s Latin American affiliate in 2014.
Founder and Managing Director
Mr. Solel founded Solpharma in 2003. As its Managing Director he has built the company’s global network of business contacts and continues to expand it through strategic partnerships. An experienced executive in international trading, Mr. Solel guides clients through the implementation of agreements and helps leverage existing cooperation in additional fields. In 2010, Mr. Solel initiated and led Ativa Pharma, a marketing and distribution company in Mexico later acquired by Grupo Somar, an Endo affiliate. Prior to establishing Solpharma, Mr. Solel acted as Managing Partner at Veropharma.
Marketing and Business Development Director
Mr.Bry joined Solpharma in 2010, bringing with him 8 years of experience in international business development in EMEA. At Solpharma he leads business development activities for emerging markets in Asia, Africa, CIS and Latin America. Mr. Bry supports clients by formulating international marketing and business plans and additionally scouts new products for local distribution partners. Mr. Bry’s MA is from Sorbonne University, Paris.